United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/786,209	02/25/2004	Alejandro Dee	10004.512	3041	
39231 SMITH LAW (7590 06/06/200 OFFICE	7	EXAMINER		
440 SCIENCE DR.			LEVY, NEIL S		
SUITE 302 MADISON, WI 53711			ART UNIT	PAPER NUMBER	
			. 1615		
			MAIL DATE	DELIVERY MODE	
			06/06/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
	10/786,209	DEE ET AL.				
Office Action Summary	Examiner	Art Unit				
•	NEIL LEVY	1615				
The MAILING DATE of this communication app						
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DV. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period v. - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be timused and will expire SIX (6) MONTHS from a cause the application to become ABANDONE!	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 25 A	Responsive to communication(s) filed on <u>25 April 2007</u> .					
2a) This action is FINAL . 2b) ⊠ This	This action is FINAL . 2b)⊠ This action is non-final.					
•	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
 4) Claim(s) 1-17,19,20,22-25,27 and 28 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) 1-4,6-17,19,20,22-25,27 and 28 is/are rejected. 7) Claim(s) 5 is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement. 						
Application Papers						
9) The specification is objected to by the Examine						
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment(s)	•					
1) Notice of References Cited (PTO-892)	4) Interview Summary					
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 	Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:					

Art Unit: 1615

DETAILED ACTION

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claim Rejections - 35 USC § 112The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claim11-17, 19, 20, 22-25, 27, 28 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for specific compounds @ specific mixes of fatty acids, @ pH<4, does not reasonably provide enablement for dielectric >25. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to practice the invention commensurate in scope with these claims.

There is no support in the specification for more than 25 being effective, unless the mix is 1% fatty acid C8/C10 at pH less than 4.0, contrary to applicant's arguments.

The factors to be considered in determining whether a disclosure meets the enablement requirement of 38 U. S. C. 112, the first paragraph have been described inn re Wands, 8 USPQ2D 1400 (Fed Cir. 1988). Among these factors are (1) the nature of the invention; (2) the state of the prior art; (3) the relative skill of those in the art; (4) the predictability or unpredictability of the art; (5) the breadth of the claims. (6) the amount of direction or guidance presented; (7) the presence or absence of working examples; and (8) the quantity of experimentation necessary. When the above factors are weighed, it is the examiner's position that instant disclosure fails to meet the enablement requirement for the following reasons:

- (1) The nature of the invention: claims are to mastitis reduction,
- (2) The state of the prior art shows the use of these compounds for antimicrobial efficacy
- (3) The relative skill of those in the art. The relative skill of those in the art is high.
- (4) The predictability or unpredictability of the art. The unpredictability of the art is high.

Application/Control Number: 10/786,209

Art Unit: 1615

(5) The breadth of the claims. The claims are very broad, as a range of ingredients with dielectric constants above, below the claimed 25, in concert with a range of specific mixes of c8/c10 fatty acids, at specific pH has not been performed.

- (6) The amount of direction or guidance presented. There is direction, as indicated above.
- (7) The presence or absence or working examples. There are limited examples.
- (8) The quantity of experimentation necessary extensivethere is no efficacy data, just correlative

Claim12 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Ethylene is not a polar solvent.

Claim1-4, 6-12, 15-17, 19, 20, 22-25, 28 stand rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over KABARA Here are topical compositions applied to teats and skin to reduce mastitis by spraying, dipping, wiping onto the area to be treated (page 6, lines 27-32).

The invention has esters at 0.5-5% (page 5, lines 11-19 and fatty acids at 1:10-10:1 of fatty acids, thus 5% fatty acid, inclusive of (Example 1) caprylic/capric mix. The ester can be seen as a secondary solvent. Carriers include alcohols (claim 9, page 5, lines 30-35) selected from propylene glycol; water is an additional carrier (page 6, top). The alcohol is 60% (page 6, lines 4-6)preferred, but can be any suitable level. Thus, 0.5% ester, 5% fatty acid, 60% propylene glycol leaves 34% water (page 6, top).

Examples show 0.5-8% caprylic/capric acid, 10-30% propylene glycol. Preservatives, EDTA and surfactants are added according to the form of composition desired (page 5, lines 23-31, 36-57). These are permitted in the instant open guise. The dielectric constant claims are met with propylene glycol.

Art Unit: 1615

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. ANDREWS also has udder and teat dips (column 2, top) and acid mix (column 3, top lines 34-42) with 80% propylene glycol (column 4, lines 7-9).

Response to Arguments

Claim 5 is not evident in the prior art record. Arguments have been considered in the rejections maintained.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to NEIL LEVY whose telephone number is 571-272-0619. The examiner can normally be reached on Tuesday-Friday, 7 AM to 5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, MICHAEL WOODWARD can be reached on 571-272-8373. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/786,209 Page 5

Art Unit: 1615

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

NEIL LEVY
Primary Examiner
Art Unit 1615